Thomas J. Schaefer
Known title: Chief Financial OfficerCIK: 0001960808
Thomas J. Schaefer's purchase track record
How the stock did after each of Thomas J. Schaefer's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since February 1, 2023
Stock higher 6 months later
40%
3 months: 20%
Median 6-month return
-13.2%
3 months: -22.6%
Beat the S&P 500
40%
median -18.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/3/2025 | RKDA | $2K | -22.6% | -13.2% | +5.6% |
| 8/1/2024 | RKDA | $1K | +31.4% | +74.4% | +11.5% |
| 2/1/2024 | RKDA | $1K | -17.8% | +21.1% | +11.0% |
| 8/4/2023 | RKDA | $2K | -26.0% | -45.5% | +10.7% |
| 2/1/2023 | RKDA | $161 | -46.1% | -59.8% | +9.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RKDA | ▲ Buy | Open Market | 700 | $2K | 2/3/2025 | View on chart |
| RKDA | ▲ Buy | Open Market | 700 | $1K | 8/1/2024 | View on chart |
| RKDA | ▲ Buy | Open Market | 700 | $1K | 2/1/2024 | View on chart |
| RKDA | ▲ Buy | Open Market | 649 | $2K | 8/4/2023 | View on chart |
| RKDA | ▲ Buy | Open Market | 700 | $161 | 2/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Arcadia Biosciences sees unusual volume and new 15.7% stake by MJL Manager
Arcadia Biosciences traded with higher than normal volume during Wednesday’s session, drawing attention from market watchers. A Form 13G filing revealed that MJL Manager now owns 15.7% of the company as of August 13, adding a new significant shareholder. The move could influence investor perception and liquidity. The stock remains below its 52‑week low, with an RSI of 26.0.
Arcadia Biosciences sees unusual volume and new 15.7% stake by MJL Manager. Arcadia Biosciences traded with higher than normal volume during Wednesday’s session, drawing attention from market watchers. A Form 13G filing revealed that MJL Manager now owns 15.7% of the company as of August 13, adding a new significant shareholder. The move could influence investor perception and liquidity. The stock remains below its 52‑week low, with an RSI of 26.0.